The European stocks experienced a decline on Tuesday, as the Stoxx Europe 600 index fell 0.23% to 456.90. The French CAC 40 index weakened 0.34% to 7,254.72, while the German DAX dropped 0.34% to 15,771.71 and the FTSE 100 index weakened 0.20% to 7,437.93.
Decreases in Stock Values
Media/entertainment company Viaplay Group AB Series B saw the largest decrease on Tuesday, with shares weakening by 9.9%. Electric utilities firm Oersted A/S and health care/life sciences company GN Store Nord A/S also experienced declines of 8.3% and 7.6% respectively.
Commerzbank AG, a banking company, and retail business Koninklijke Ahold Delhaize N.V. rounded out the top five largest decreases with their stocks falling by 6.1%.
Increases in Stock Values
Partners Group Holding AG saw the largest increase among the Stoxx Europe 600 constituents, as shares added 6.6% on Tuesday. Retail firm Etablissementen Franz Colruyt N.V. and retail company DocMorris N.V. also experienced increases of 6.0% and 5.4% respectively.
Alten, a business/consumer services company, and health care/life sciences company MorphoSys AG rounded out the top five largest increases with their stocks adding 3.6% and 3.3% respectively.
Currency and Commodity Market Updates
The pound was down 0.35% against the dollar, while the euro was down 0.62%. In the commodity market, Brent crude gained 2.22% to reach $90.98.
Bond Yield Updates
The yield on the 10-year gilt increased 5.57 basis points to 4.524%, and the yield on the German 10-year bund increased 3.070 basis points to 2.61%.
Revisions to U.K. Growth Data Spark Investor Interest
Our Latest News
Las Vegas Sands: Impressive Revenue Surge in Q4
Las Vegas Sands reports a net profit of $382 million in Q4, surpassing analysts' expectations. CEO Robert Goldstein remains optimistic about growth in Macao and...
Cryptocurrency Market Update
Large cryptocurrencies experienced mixed results during morning trading. Uniswap dropped while Polygon led the way with a climb.
Acadia Pharmaceuticals Inc.: Drug Trial Disappointment
Acadia Pharmaceuticals Inc. experiences a 15% drop in stock after pimavanserin fails in a schizophrenia treatment trial. CEO shares disappointment and future pl...